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Background
Moonmilk is a karstic speleothem mainly composed of fine calcium carbonate crystals (CaCO3) with different textures ranging from pasty to hard, in which the contribution of biotic rock-building processes is
presumed to involve indigenous filamentous microorganisms. Moonmilk deposits of limestone caves host a rich microbiome, among which Actinobacteria represent one of the most abundant phyla and making
moonmilk an appealing unexplored biotope for bioprospecting of rare and novel Actinobacteria as possible producers of new molecules with therapeutical properties. Moreover, ancient medical texts reported
that moonmilk had therapeutical properties, thereby suggesting that its filamentous endemic actinobacterial population might be a source of natural products useful in human treatment. This poster illustrates
the different steps of our project aiming at i) isolating and characterizing moonmilk dwelling actinobacteria, and ii) investigating their capability at producing compounds with antimicrobial properties.
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Production, extraction, purification and identification compounds with antimicrobial properties
1st D: Ion exchange LC 2nd D: RP C18 HPLC
Inhibitory activity test of the crude extract
MM-strains are used in
cross-streak assays against
bacterial and fungal
pathogens in order to
detect antimicrobial
activities under the tested
conditions.
Activity screening 
Plates are inoculated with the test microorganism (here
Saccharomyces cerevisiae) and the crude extract of the
culture supernatant is added on paper discs.
Active fraction identification on 2D-LC off
Pure (?) 
compounds
MS/MS fragmentation of an unknown anti-gram positive compound with a m/z of 819.4868 UMA
MS spectra of an anti-yeast compound with a m/z of 281.1621 UMA
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UPLC-MS
Isolation and phylogeny of Moonmilk-dwelling Streptomyces isolates
Cave ‘Grotte des Collemboles’ and Moonmilk collection 
points
Cave entrance
COL3COL1 COL4
Comblain-au-Pont
Filament-forming microorganism within 
moonmilk
Map of the cave and position/visualization of the different moonmilk deposit 
sampling points. 
Cryo-scanning electron micrographs (ESEM) of nano-size 
filaments found in moonmilk deposits
Multilocus sequence analysis (MLSA) of moonmilk isolates and 
phenotypes of the selected representative of each phylotype
Antimicrobial screening 
The size of the inhibition zone (in cm) is indicated for each moonmilk isolate and related to a color scale. Isolates causing impaired growth of the tested bacteria are indicated by a yellow triangle, inhibition effects
combining both impaired growth and growth inhibition are marked with a green circle, and clear bactericidal growth inhibition effects are not marked with any symbol. The fields selected with a black border refer to
the chosen examples of the cross-streak results displayed below the heatmap. x, the tested pathogen cannot grow in the chosen medium; ng, no or poor growth of the moonmilk isolate.
Heatmap illustrating the strength of the antibacterial and antifungal activities of representatives of the 31 phylotypes Antimicrobial (pre)disposition of moonmilk phylotypes
Mean of the antifungal and antibacterial activities for each phylotype representatives, together
with the sum of those activities. The greyscale on the heatmap displays the biosynthetic NRPS
and PKS type genes content of individual strains.
Conclusions and Perspectives MM122Tautomycetin TPU 0037-A (also D and C)
Skyllamycin A (also B)
MM99 Cycloheximide (also
Dehydrocycloheximide and 
actiphenol)
Gilvocarcin(a) 
Respinomycin D 
Unknown antimicrobial agents (m/z)
429.2848
Unknown antimicrobial agents (m/z)
202.1805
225.196
783.4891
819.4868
814.5307
Antismash analyses on the genome of MM99 (on the left) and MM122 (on the right). Gene cluster for novel metabolite
Phylogenetic analysis revealed that all actinobacterial isolates were exclusively affiliated to the
genus Streptomyces and clustered into 31 distinct phylotypes displaying various pigmentation
patterns and morphological features. The moonmilk Streptomyces collection was found to
display strong inhibitory activities against a wide range of reference organisms, as 94, 71, and
94% of the isolates inhibited or impaired the growth of Gram-positive, Gram-negative bacteria,
and fungi, respectively. Overall, our work supports the common belief that moonmilk might
effectively treat various infectious diseases thanks to the presence of a highly diverse
population of prolific antimicrobial producing Streptomyces. Current analyses reveal/suggest
that each isolate from our collection secretes antimicrobial compounds with masses that do
not correspond to known molecules and display many cryptic metabolite biosynthesis gene
clusters, which confirms that moonmilk may indeed constitute a promising reservoir of
potentially novel natural compounds.
